


6/13

10/508873

Fig.2.



7/13

Fig.3.





Fig.4.

CDK4 PROTEIN STRUCTURE (303aa)



6-295

Protein kinase domain

12,20 & 35-ATP binding site

24(V)-p16^{INK4A} Variant site (R->C in somatic and familial melanoma, generates Arg²⁴->cys, a dominant oncogene resistant to inhibition by p16)

42,48-polygly domain

56,140,142-active site

Gln98, Asp 99 Thr102-p16 binding region

17-Tyr phosphate binding site

172-Thr phosphate binding site (necessary for kinase activity)

285-Ser phosphate binding site

9/13

Fig.5.






Fig.7.



10/13

Fig.6.



11/13

Fig.8.




Fig.11A.

Changes in protein expression of Phosphorylated Retinoblastoma Protein p110 [A] and p105 [B] following cell plating





Fig.11B.



Changes in the Phosphorylated Retinoblastoma protein product p110 at times of 4, 8, 16, 24, 40 and 48 hours following cell plating. (pRb retinoblastoma p110 mouse monoclonal antibody IF8. Santa Cruz Biotechnology.CA.USA. pRb retinoblastoma p105 mouse monoclonal antibody NCL-RB-358. Novacastra. Tyneside. UK)

12/13

Fig.9.




Fig.10A.




Fig.10B.




Fig.10C.




Fig.10D.




Fig.12.

